We demonstrate a newly-developed magneto-fluorescent carbon nanotube (CNT)-mediated siRNA (CNTsiRNA) delivery system, which significantly silences our target of interest, gastrin-releasing peptide receptor (GRP-R), in neuroblastoma. CNT-siGRP-R resulted in a 50% silencing efficiency and a sustained efficacy of 9 days for one-time siRNA treatment in vitro, whereas siRNA delivered by the commercial transfection reagent couldn't knockdown GRP-R expression. We further show that CNT-siRNA efficiently inhibits the growth of subcutaneous xenograft tumors in vivo. This system allows us to track the CNT-siRNA distribution via both near-infrared fluorescence and magnetic resonance imaging. Moreover, our delivery system can be used to knockdown GRP-R expression in other cancer cell types, such as human breast cancer cells. The high efficiency and sustained efficacy may indicate that the natural stacking interactions between CNTs and siRNAs can protect siRNAs from degradation and enhance their stability during the delivery process.
Introduction
Neuroblastoma is the most common extracranial solid tumor in infants and children, which can arise anywhere along the sympathetic chain and is frequently found in the adrenal medulla and paraspinal ganglia. 1 We have previously demonstrated that small interfering RNA (siRNA)-mediated gastrinreleasing peptide receptor (GRP-R) silencing can significantly suppress tumorigenesis and metastatic potential in murine models of neuroblastoma. 2 However, the clinical applications of siRNA therapeutics have been impeded by its poor intracellular uptake, instability in vivo, and non-specific immune stimulations. To address these issues, various systems such as lipid-like materials, triblock nanocarriers, modified gold nanoparticles, and quantum dots have been developed for siRNA delivery in vitro and in vivo. [3] [4] [5] [6] [7] [8] [9] Among them, carbon nanotubes (CNTs) have gained significant interest as a promising tool for siRNA delivery due to their capability to cross cell membranes. 10, 11 Moreover, DNA and RNA molecules can naturally wrap around CNTs through the non-covalent p-p stacking interactions between base pairs and CNT sidewalls. [12] [13] [14] [15] Stable CNT aqueous suspensions formed by coating as-grown CNTs with single-stranded DNA (ssDNA) (Fig. 1A ) have been used to deliver siRNA to target specific genes and to retard the growth of established tumors. 16, 17 In order to avoid the interference between the ssDNA used to suspend CNTs and the subsequent siRNA-mediated target silencing, various biocompatible polymers have been used to decorate CNT sidewalls to form stable functionalized-CNT suspensions, which are then conjugated with siRNA oligonucleotides by covalent bonding (Fig. 1B) . [18] [19] [20] [21] [22] [23] [24] These covalentlyconjugated CNT-siRNA systems have shown the capabilities to knock down specific gene expression, and then to inhibit cell proliferation and tumor progression. 10, 11, [18] [19] [20] [21] [22] [23] [24] [25] In addition,
CNTs have been used as fluorescence imaging agents due to their intrinsic non-bleaching near infrared fluorescence (NIRF) [26] [27] [28] [29] [30] [31] [32] [33] and as magnetic resonance imaging (MRI) contrast agents owing to the magnetic metal catalysts attached to the ends of CNTs. [32] [33] [34] [35] [36] [37] [38] All of these unique intrinsic properties make CNTs ideal candidates for siRNA delivery while their treatment effect can be simultaneously monitored by a variety of imaging methods.
In this study, we developed a magneto-fluorescent CNTsiRNA delivery system for cellular imaging and GRP-R silencing in neuroblastoma, where CNTs were initially suspended by lipo-polyethylene glycol chains (PEG) and then naturally wrapped by siRNA oligonucleotides through noncovalent p-p stacking interactions (Fig. 1C) . The intrinsic NIRF and MRI of PEG-functionalized-CNTs (PEG-CNTs) allowed us to track the CNT distribution during the siRNA delivery process. We demonstrated that CNT-siRNA delivery was able to significantly silence target GRP-R in neuroblastoma cells with a 50% silencing efficiency and a sustained efficacy of 9 days for one-time CNT-siRNA treatment, whereas siRNA delivered by the standard transfection method couldn't knockdown GRP-R expression. We further showed that CNT-siRNA efficiently inhibited the growth of subcutaneous xenograft tumors in vivo. Moreover, our CNT-siRNA delivery system can be used for delivery in other types of cancer cells. CNT-siRNA exhibited the capability to reduce GRP-R expression down to 11% in human breast cancer cells, approximately 5 times more efficient than siRNA mediated by the commercial transfection reagent (Lipofectamine TM 2000, LIPO). This high efficiency and sustained efficacy may result from the natural stacking interactions between CNTs and siRNAs that can protect siRNAs from degradation and enhance their stability during delivery.
Results and discussion

Functionalization of CNTs
Recently, many surfactants have been used to disperse hydrophobic as-grown CNTs in solution. 11, 39, 40 Among them, PEG-CNTs have been used to deliver various biologically active molecules into cells 10, 11 and non-covalently conjugated PEGCNTs have been tested as a 'least toxic scenario' in mice. 41 Here, PEG without an active functional group was used to suspend as-grown HiPco CNTs (single-walled carbon nanotubes with typical length of 100-400 nm and diameter of 1 nm) in solution, where a PEG molecule binds strongly to a CNT sidewall via non-covalent absorption to form a PEG-CNT. siRNA oligonucleotides penetrate into the PEG coating and wrap around CNTs through non-covalent p-p stacking interactions [12] [13] [14] [15] between base pairs and CNT sidewalls (Fig. 1C) .
CNTs for dual-modality imaging of neuroblastoma cells
In order to evaluate the efficacy of treatment and to improve the pharmacokinetic profile of a drug, it is important for a drug-carrier to be detected by using a variety of imaging methodologies. In this study, we performed MRI of PEG-CNTs and visualized the CNT/CNT-siRNA distribution in tumor cells via both NIRF and MRI. As-produced CNTs possess metal catalyst nanoparticles at their ends, which can reduce the spin-spin relaxation time of water protons nearby and make CNTs inherent T 2 -weighted MRI contrast agents. The T 2 -weighted MRI T 2 maps with various PEG-CNT concentrations are illustrated in Fig. 2A . The presence of PEG-CNTs had a significant effect on the T 2 relaxation time, as commonly observed with iron-based MRI contrast agents. The concentration of iron nanoparticles that attach to the ends of PEG-CNTs was approximately 10 wt% through the inductively coupled plasma optical emission spectrometry (ICP-OES) measurements. The T 2 -relaxivity in terms of iron was about 60 s 21 /(mM l 21 ), which is comparable to that of the commercial MRI contrast agent Ferumoxtran-10 (r 2 = 65 s 21 /(mM l 21 )). To examine the effectiveness of cellular imaging by using CNTs as an MRI contrast agent, we transfected human neuroblastoma BE(2)-C cells with CNT-siGRP-R. Cells were trypsinized and resuspended into 0.4% agarose gels at 48 h post-transfection. As shown in Fig. 2B , the samples were prepared with BE(2)-C cells that were treated with CNT-siRNA (Fig. 2B , left) and PBS (Fig. 2B, right) , respectively. The T 2 relaxation times of cells containing CNTs (236.6 ¡ 0.8 ms) were lower than those without CNT-siRNA treatment (245.9 ¡ 1.4 ms). This indicates that the accumulation and distribution of CNTs can be simultaneously tracked through MRI during the siRNA delivery process.
To demonstrate the feasibility of tracking the CNT distribution via NIRF imaging during delivery, BE(2)-C cells were transfected with CNT-siGRP-R, and resuspended in 0.4% agarose gels at 48 h post-transfection. The cell imaging was then carried out in the range of 1150-1700 nm by employing the intrinsic NIRF of CNTs. Fig. 2C shows false color-coded fluorescence images of the cells, obtained by stacking a z-series of images with 10 s exposure time each and overlaid by the corresponding optical cell images. This image clearly showed that CNT-siGRP-R has been efficiently delivered into the cells. Our experimental results indicate that both intrinsic NIRF and MRI of CNTs in our delivery system can be used to track the distribution of drug carriers (CNTs) and to estimate the delivery efficiency.
CNT-siRNA silence target gene in neuroblastoma in vitro and in vivo
After validating that CNT-siRNA could be visualized in cells during delivery via both NIRF and MRI, we examined the drug delivery efficiency of CNT-siRNA in human neuroblastoma BE(2)-C cells. We transfected BE(2)-C cells with LIPO-mediated siCON (LIPO-siCON), LIPO-siGRP-R, CNT-siCON, CNT-siGRP-R, naked-siCON and naked-siGRP-R, respectively. Protein samples were collected from whole cell lysates that were collected at 2 and 9 days post-transfection, respectively, and were analyzed with Western blotting. As shown in Fig. 3A , CNT-siGRP-R significantly downregulated GRP-R expression 2 days after transfection, whereas both naked-siGRP-R and commercial transfection reagent LIPO-siGRP-R did not knockdown GRP-R expression. Moreover, the GRP-R silencing efficiency mediated by CNT-siRNA was persistently high at 9 days post-transfection, when most siRNA delivery systems cannot silence target genes for that duration due to the instability of siRNA. The sustained efficacy for one-time treatment is critical for drug delivery in clinical applications, since high efficacy and low frequency treatments can reduce the likelihood of drug toxicity in humans.
To evaluate the efficacy of GRP-R silencing mediated by CNT-siRNA in vivo, we performed CNT-siRNA delivery locally into subcutaneous tumors, which were established with luciferase expressing neuroblastoma BE(2)-C cells in athymic nude mice as described previously.
2 CNT-siCON and CNTsiGRP-R that were prepared as described in the Methods section were injected into tumors directly. The effects of these drugs on downregulation of GRP-R and inhibition of tumor growth were examined. In vivo bioluminescence imaging was performed as previously described. 42 The substrate luciferin was injected into the intraperitoneal cavity at a dosage of 150 mg kg 21 body weight (30 mg ml 21 luciferin) approximately 5 min before imaging. Mice were imaged before, 5 and 27 days after a single administration of CNT-siRNA. Injection of these two siRNA drugs produced significant effects on the tumor sizes in vivo (Fig. 3B, C) . CNT-siGRP-R efficiently decreased the tumor size 5 days post-injection and significantly inhibited the tumor growth 27 days post-injection as compared to controls treated with CNT-siCON. To validate whether the GRP-R expression was affected in the tumors by CNT-siGRP-R treatment, immunohistochemistry (IHC) was performed. The expression of target GRP-R protein levels was significantly decreased in CNT-siGRP-R treated tumors (Fig. 3E ) compared to CNT-siCON controls (Fig. 3D) , which was consistent with our in vitro results. Moreover, we found that cells in CNTsiGRP-R treated tumors appeared to lose cell-cell adhesion, and were more differentiated on morphological observation (Fig. 3G) . Additionally, paraffin-embedded sections were stained with anti-human phosphor-Histone H3 (Ser10) antibody and followed by Alexa Fluor 568 Dye. DAPI (49,6-diamidino-2-phenylindole dihydrochloride) was used for staining nuclei. Phosphor-Histone H3 (Ser10) is a cell mitosis marker, which is tightly correlated with chromosome condensation during both mitosis and meiosis. [43] [44] [45] As shown in 
Delivery efficiency in other types of cancer cells
In addition to neuroblastoma, GRP-R is highly expressed in other neuroendocrine tumors, including breast cancer. 46 Therefore, we wanted to investigate the delivery efficiency of CNT-siRNA in other types of cancer cells. Using human breast cancer MDA-MB-231 cells, we found that GRP-R expression was significantly knocked down to 11% at 96 h posttransfection by CNT-siGRP-R (Fig. 4) , which was significantly more effective than GRP-R silencing by LIPO-siGRP-R (55%). In addition, we found that CNT-siGRP-R could efficiently downregulate AKT2, which is the downstream target of GRP-R, 2 correlating with chemoresistance. 47 These results indicate that the downstream signaling pathway of GRP/GRP-R can be blocked by CNT-siGRP-R. This observation further corroborates that CNT-siRNA delivery is broadly relevant for various cancer cell types. The sustained efficacy and high delivery efficiency of CNT-siRNA make it a promising delivery system for clinical applications.
Conclusions
The key challenges for GRP-R mediated siRNA therapy in neuroblastoma are the delivery efficacy 48 and simultaneous evaluation of the treatment effect. It is desirable to develop a therapeutic strategy to stabilize siRNA, to deliver siRNA into cells, to silence the target oncogene, to inhibit tumor growth and metastasis, and to detect the biodistribution of siRNA through the intrinsic properties of drug-carriers. In the present study, we developed a magneto-fluorescent CNT-siRNA delivery system for cellular imaging and GRP-R silencing in neuroblastoma. In our novel system, CNTs were initially suspended by PEG to improve their cytocompatibility and bioavailability, and then naturally wrapped with siRNA oligonucleotides through non-covalent p-p stacking interactions to protect siRNAs from degradation. We visualized the distribution of CNT/CNT-siRNA via both intrinsic NIRF and MRI of CNTs during CNT-siRNA delivery. CNT-siRNA delivery was able to significantly silence the target GRP-R in neuroblastoma with a high delivery efficiency and sustained efficacy of 9 days, whereas siRNA delivered by the standard delivery method couldn't knockdown GRP-R expression. To the best of our knowledge, a sustained efficacy of 9 days is the longest recorded for one-time siRNA treatment on cells, which may be particularly important for future clinical applications of siRNA since high efficacy and low frequency treatments can potentially reduce drug toxicity in patients. We further showed that CNT-siRNA can efficiently inhibit the growth of mouse subcutaneous xenograft tumors in vivo. Aside from neuroblastoma, CNT-siRNA was also able to reduce GRP-R expression in human breast cancer cells with a reduction rate 5 times more than siRNA mediated by the commercial transfection reagent LIPO. This high efficiency and sustained efficacy of CNT-siRNA may result from the natural stacking interactions between CNTs and siRNAs that can protect siRNAs from degradation and enhance their stability during delivery.
Methods
Preparation of functionalized-CNTs
CNTs were produced by the high-pressure CO (HiPco) process at Rice University. PEG (1,2-distearoyl-sn-glycero-3-phos- nm. 11 The extra PEG in the CNT solution was removed by water washing through centrifugal filter devices at 4000 g and 4 uC for 10 min; this process was repeated a few times and PEG-CNTs were resuspended in the PBS buffer. PEG-CNTs are ready to be wrapped with siRNA through non-covalent stacking interactions.
CNT-siRNA preparation antisense: 39-dTdTGAAUGCGACUCAUGAAGCU-59. The siRNA solution was prepared by dissolving siRNA in RNase-free water to a final concentration of 100 mM for storage. Then, 15 ml of 100 mM siRNA was added to the PEG-CNT solution to reach a siRNA concentration of 1.7 mM in PBS and incubated at 4 uC for 24 h. The final CNT and siRNA concentrations were approximately 20 mg L 21 and 1.7 mM, respectively. The CNTsiRNA solution was ready for cell transfection.
Cell culture and transfections
Human neuroblastoma BE(2)-C and breast cancer MDA-MB-231 cell lines were purchased from American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI 1640 medium with L-glutamine (Cellgro Mediatech, Inc. Herndon, VA) supplemented with 10% fetal bovine serum (FBS, Sigma). Cells were maintained at 37 uC in a humidified atmosphere of 95% air and 5% CO 2 . For transfection, cells were plated in 6-well plates in 1.5 ml medium overnight and reached 70% confluence. Then, 0.5 ml of CNT-siRNA solution was added into the cell cultures, in which the final concentrations of CNT and siRNA were 5 mg L 21 and 0.425 mM, respectively. The cells were then incubated for various indicated time intervals, and collected for target silencing measurements using Western blot analysis.
Cell preparation for NIRF and MRI
Cells with or without the CNT-siRNA treatments were trypsinized and washed with culture medium via centrifugation at 200 g and room temperature for 5 min and resuspended at the concentration of 2 6 10 6 cells ml 
MRI of CNTs and CNT-siRNA treated cells
MRI was studied with a 4.7 T 31 cm bore Varian Direct Drive scanner at the Vanderbilt University Institute of Imaging Science, which is a fully broad-banded imaging/spectroscopy system equipped with actively shielded gradients (40 G cm
21
, rise time full amplitude of 130 ms), two independent transmit channels and one independent receive channel. For MRI of CNTs, the T 2 signal decay was measured using a Carr-PurcellMeiboom-Gill (CPMG) spin-echo pulse sequence with N = 16 echoes with 8 ms echo spacing. The signal from each voxel at the 16 imaging time points was fit to a monoexponential signal decay model to determine T 2 for each voxel:
S~S 0 e {t = T 2 . A region of interest (ROI) was manually drawn using Matlab (MathWorks, Inc, Natick, MA) for the first imaging time point and translated to the images from later echoes. The mean T 2 and standard deviation for each sample was calculated from all voxels within this ROI. Other imaging parameters included T R = 3 s, field of view = 32 6 32 mm, data matrix = 128 6 128, tube thickness = 3 mm and number of acquisitions = 4 (total scan time y26 min). For MRI of cells, the T 2 signal decay was measured with N = 32 echoes with 8 ms echo spacing, T R = 2500 ms, field of view = 32 6 32 mm, data matrix = 128 6 128 (250 micron in plane resolution), slice thickness = 1.5 mm and number of acquisitions = 12.
Western blot analysis for GRP-R and AKT2 
CNT-siRNA delivery into subcutaneous xenograft Tumors in vivo
All experiments were approved by the Institutional Animal Care and Use Committee in accordance with guidelines issued by the National Institutes of Health. Male athymic nude mice (4-6 weeks old) were maintained as described. 49 BE(2)-C xenografts were established as previously described. 2, 49 Briefly, BE(2)-C cells (1 6 10 6 ) in 100 ml of HBSS were injected into the bilateral flanks using a 26-gauge needle (n = 3-5 per group). CNT-siRNA treatments were performed from day 7 post-tumor cell inoculation in mice. Then, 50 ml of the CNT-siRNA PBS solution with concentrations at 20 mg L 21 for CNTs and 1.7
mM for siRNA was injected into each tumor. At sacrifice, tumors were harvested for analysis.
In vivo bioluminescence Imaging
In vivo bioluminescence imaging was performed as previously described. 42 The substrate luciferin (30 mg ml 21 ) was injected into the intraperitoneal cavity at a dose of 150 mg kg 21 body weight approximately 5 min before imaging. Mice were anesthetized with isoflurane/oxygen and placed on the imaging stage. Images were collected for 1 to 5 s using the Xenogen IVIS 200 bioluminescent imaging system (Xenogen Corp., Alameda, CA). Photons emitted from the tumor region were quantified using Living Image software (Xenogen Corp.).
Immunohistochemistry
Immunohistochemical staining was performed using DAKO EnVision+ System-HRP from Dako North America, Inc. (Carpinteria, CA). Mouse neuroblastoma xenografts were fixed in formalin overnight and embedded in paraffin wax. Tumor sections (5 mm) were mounted on glass slides. Sections were deparaffinized with xylene, rehydrated with ethanol, antigen retrieval performed with 10 mM sodium citrate buffer, and then blocked with blocking solution for 20 min at room temperature. Slides were incubated with GRP-R primary antibody overnight at 4 uC. They were then washed with buffer three times for 5 min each and incubated with secondary antibody for 30 min at room temperature. Sections were developed with DAB reagent. The reaction was terminated by immersing slides in dH 2 O and sections were counterstained with hematoxylin. Slides were then dehydrated with ethanol and xylene. Coverslips were mounted and slides were left to dry. The IHC images were taken under a microscope (Leica DMI6000 B). For mitosis detection, paraffin-embedded sections were stained with anti-human phospho-histone H3 (Ser10) antibody followed by Alexa Fluor 568 Dye (Life Technologies, Grand Island, NY). DAPI was used for staining nuclei. Images were captured using a fluorescence microscope (Nikon Eclipse E600).
